The Latest Analyst Ratings for Ascendis Pharma
Portfolio Pulse from Benzinga Insights
Ascendis Pharma (NASDAQ:ASND) has received 10 analyst ratings in the last quarter, with 4 somewhat bullish and 6 indifferent. The company's average 12-month price target is $128.8, which has increased by 5.14% over the past month.
October 09, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma has received 10 analyst ratings in the last quarter, with 4 somewhat bullish and 6 indifferent. The average 12-month price target is $128.8, up 5.14% over the past month.
The increase in the average 12-month price target and the somewhat bullish ratings from analysts suggest a positive outlook for Ascendis Pharma. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100